Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Improvement of metabolic risk profile under second-generation antipsychotics: a pilot intervention study.

Blouin M, Binet M, Bouchard RH, Roy MA, Després JP, Alméras N.

Can J Psychiatry. 2009 Apr;54(4):275-9.

PMID:
19321034
2.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
3.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
4.
5.

Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.

Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M.

J Clin Psychiatry. 2004 Apr;65(4):471-7.

PMID:
15119908
6.

Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?

Correll CU.

J Clin Psychiatry. 2005 Oct;66(10):1331-2. No abstract available.

PMID:
16259549
7.

Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.

Roy G, Bedard A, Desmarais PA, Jourdain F, Allen S, Michaud D, Ben Amor L.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):479-87. doi: 10.1089/cap.2010.0011.

PMID:
21186966
8.

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.

Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P.

Am J Psychiatry. 2005 Jun;162(6):1217-21.

PMID:
15930076
9.

Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.

de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):166-73. doi: 10.1089/cap.2011.0079.

PMID:
22506734
10.

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.

Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C.

Bipolar Disord. 2010 Mar;12(2):172-84. doi: 10.1111/j.1399-5618.2010.00797.x.

PMID:
20402710
11.

Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.

Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH.

J Clin Psychiatry. 2004 Apr;65(4):557-64.

PMID:
15119921
12.

Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.

Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, Ujkaj M, Pastorelli F, Berardi D.

BMC Psychiatry. 2006 Mar 16;6:11.

13.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, Thiébaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
14.

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.

Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B.

J Clin Psychiatry. 2006 Aug;67(8):1253-60.

PMID:
16965204
15.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
16.

Is practice rate rather than exercise intensity more important in health benefits of moderately obese postmenopausal women?

Garnier S, Joffroy S, Gaubert I, Sanguignol F, Auneau G, Guiraud T, Mauriège P.

Ann Phys Rehabil Med. 2015 Jun;58(3):119-25. doi: 10.1016/j.rehab.2015.03.003. Epub 2015 May 23.

17.

Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.

Engelson ES, Agin D, Kenya S, Werber-Zion G, Luty B, Albu JB, Kotler DP.

Metabolism. 2006 Oct;55(10):1327-36.

PMID:
16979403
18.

Obesity and coronary risk in patients treated with second-generation antipsychotics.

Correll CU, Kane JM, Manu P.

Eur Arch Psychiatry Clin Neurosci. 2011 Sep;261(6):417-23. doi: 10.1007/s00406-010-0177-z. Epub 2010 Dec 12.

20.

Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.

Park T, Usher K, Foster K.

Int J Ment Health Nurs. 2011 Dec;20(6):428-37. doi: 10.1111/j.1447-0349.2011.00747.x. Epub 2011 May 12.

PMID:
21564457

Supplemental Content

Support Center